Clinical trial
A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine
NCT00375206 · PowderMed, Industry · Completed
Key facts
| NCT number | NCT00375206 |
|---|---|
| Title | A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine |
| Official title | A Phase I Study to Assess Safety, Tolerability and Immunogenicity of a Trivalent Influenza Vaccine Administered by Particle Mediated Epidermal Delivery (PMED) to Healthy Subjects |
| Lead sponsor | PowderMed, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012) |
| Enrollment | 189 |
| Start date | Sep 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Sep 12, 2006 |
| Last update posted | Jan 29, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: